Substance / Medication

Ethinylestradiol

Overview

Active Ingredient
ethinyl estradiol
RxNorm CUI
4124

Indications

Levonorgestrel and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Table 2 Oral contraceptives are highly effective for pregnancy prevention.lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and implants, depend upon the reliability with which they

Labeler: Glenmark Pharmaceuticals Inc., USAUpdated: 2026-01-30T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Levonorgestrel and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions : Thrombophlebitis or thromboembolic disorders History of deep-vein thrombophlebitis or thromboembolic disorders Cerebrovascular or coronary artery disease (current o

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

20 trials linked to this intervention

20
Total Trials
1
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis.
López-Picado Amanda, Lapuente Oihane, Lete Iñaki · Eur J Contracept Reprod Health Care · 2017
PMID: 28256919Meta-Analysis
Effects of estradiol- and ethinylestradiol-based contraceptives on adrenal steroids: A randomized trial.
Kangasniemi Marika H, Arffman Riikka K, Haverinen Annina et al. · Contraception · 2022
PMID: 36084710RCT
Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis.
Haverinen Annina, Luiro Kaisu, Kangasniemi Marika H et al. · J Clin Endocrinol Metab · 2022
PMID: 35279718RCT
Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial.
Haverinen Annina H, Luiro Kaisu M, Szanto Timea et al. · Acta Obstet Gynecol Scand · 2022
PMID: 35909329RCTFull text (PMC)
Comparison of change in body weight between contraception containing 30-μg ethinylestradiol/2-mg chlormadinone acetate or 30-μg ethinylestradiol/3-mg drospirenone: a randomised controlled trial.
Wongwananuruk Thanyarat, Panichyawat Nalinee, Panchalee Tachjaree et al. · Eur J Contracept Reprod Health Care · 2020
PMID: 31756117RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ethinylestradiol (substance)
SNOMED CT
126097006
UMLS CUI
C0015011
RxNorm CUI
4124
Labeler
Glenmark Pharmaceuticals Inc., USA

Clinical Data

This intervention maps to 13 entities in the Ltrl knowledge graph.

7
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
20
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.